Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-27
2011-11-01
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252110, C514S252140, C514S252180, C514S252190, C514S252200, C544S122000, C544S295000
Reexamination Certificate
active
08048881
ABSTRACT:
The invention relates to 4-aminocarbonyl-pyrimidine derivatives and their use as P2Y12receptor antagonists in the treatment and/or prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.
REFERENCES:
patent: 53-073586 (1978-06-01), None
patent: WO-02/098856 (2002-12-01), None
patent: WO-2004/052366 (2004-06-01), None
patent: WO 2008/044217 (2008-04-01), None
patent: WO 2008/050301 (2008-05-01), None
patent: WO 2009/069100 (2009-06-01), None
patent: WO 2009/125365 (2009-10-01), None
patent: WO 2009/125366 (2009-10-01), None
patent: WO 2010/116328 (2010-10-01), None
patent: WO 2010/122504 (2010-10-01), None
Vippagunta et al., Crystalline Solids, Advanced Drug Delivery Reviews, 48, pp. 3-26, 2001.
West, Solid Solutions, Solid State Chemistry and its applications, pp. 358 & 365, 1988.
Ulrich, Chapter 4: Crystallization, Kirk-Othmer Encyclopedia of Chemical Technology, pp. 1-7, Aug. 2002.
Feokistov et al., Adenosine A2B receptors, Pharmacological Reviews, vol. 49, No. 4, pp. 381-402, 1997.
Parlow J.J. et al. Bioorg Med Chem Left. Aug. 15, 2009; 19, 6148-6156. Epub Sep. 10, 2009.
Bishop, Michael J.et al.; “3-(αR)-α-((2S,5R)-4-Ally1-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-alkyl-N-arylbenzamides: Potent, Non-Peptidic Agonists of Both the μ and δ Opioid Receptors”; J. Med. Chem. 2003, 46, pp. 623-633.
Fuerstner, Alois et al.; “Iron-Catalyzed Cross-Coupling Reactions”; J. Am. Chem. Soc., vol. 124, No. 46, 2002, pp. 13856-13863.
Gould, Philip L.; “Salt selection for basic drugs”; International Journal of Pharmaceutics, 33, 1986, pp. 201-217.
Parlow J.J. et al. Bioorg Med Chem Lett. Aug. 15, 2009; 19(16):4657-63. Epub Jun. 25, 2009.
Amir, J., et al., “Treatment of Thrombotic Thrombocytopenic Pupura with Antiplatelet Drugs”, Blood, vol. 42, No. 1, pp. 27-33 Jul. 1973.
Antithrombotic Trialists' Collaboration, “Collaborative Meta-Analysis of Randomised Trials of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High Risk Patients”, British Medical Journal, vol. 324, pp. 71-86, 2002.
Balduini, C.L., et al., “Platelet Aggregation in Platelet-Rich Plasma and Whole Blood in 120 Patients with Myeloproliferative Disorders”, Coagulation and Transfusion Medicine, vol. 95, No. 1, pp. 82-86, Jan. 1991.
Bertrand, Michel. E., “Randomized Multicenter Comparison of Conventional Anticoagulation Versus Antiplatelet Therapy in Unplanned and Elective Coronary Stenting: . . . ” Circulation, vol. 98, pp. 1597-1603, 1998.
Brighton, T.A., et al., “Antiphospholipid Antibodies and Thrombosis”, Bailliere's Clinical Haematology, vol. 7, No. 3, pp. 541-557, Sep. 1994.
Caprie Steering Committee, “A Randomized, Blinded, Trial of Clopidogrel Versus Asprin in Patients at Risk of Ischaemic Events (CAPRIE)”, The Lancet, vol. 348, pp. 1329-1339, Nov. 16, 1996.
Collins, C.E. et al., “Review Article:Platelets in Inflammatory Bowel Diease-Pathogenic Role and Therapeutic Implications”, Aliment Pharmacol. Ther., vol. 11, pp. 237-247, 1997.
Davies, M.J., et al., “Intramyocardial Platelet Aggregation in Patients with Unstable Angina Suffering Sudden Ischemic Cardiac Death”, Pathophysiology and Natural History—Platelets, Circulation, vol. 73, No. 3, pp. 418-427, 1986.
Felfernig-Boehm, D., et al., “Early Detection of Preeclampsia by Determination of Platelet Aggregability”, Thrombosis Research, vol. 98, pp. 139-146, 2000.
Fox, K.A.A., et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non-ST-Elevation Acute Coronary Syndrome: The Clidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) Trial, Circulation, vol. 110, pp. 1202-1208, 2004.
Halushka, P.V., et al., “Protective Effects of Aspirin in Endotoxic Shock”, The Journal of Pharmacology and Experimental Therapeutics, vol. 218, No. 2, pp. 464-469, 1981.
Hovens, M.M.C., et al., “Aspirin in the Prevention and Treatment of Venous Thromboembolism”, Journal of Thrombosis and Haemostasis, vol. 4, pp. 1470-1475, 2006.
Kharbanda, R.K., et al., “Prevention of Inflammation-Induced Endothelial Dysfunction: A Novel Vasculo-Protective Action of Aspirin”, Circulation, vol. 105, pp. 2600-2604, 2002.
Megalopoulos, A., et al., “Recurrent Arterial Thromboses in a Woman with Heparin Induced Thrombocytopenia, Successfully Managed with Iloprost Followed by Clopidogrel. An Alternative Therapeutic Option for Heparin Induced Thrombocytopenia Type II Syndrome”, International Angiology, vol. 25, No. 1, pp. 84-89, Mar. 2006.
Mehta, S.R., et al., “Effects of Pretreatment with Clopidogrel and Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous Coronary Intervention: The PCI-CURE Study”, The Lancet, vol. 358, pp, 527-533, Aug. 18, 2001.
Payne, D.A., et al., “Beneficial Effects of Clopidogrel Combined with Aspirin in Reducing Cerebral Emboli in Patients Undergoing Carotid Endarterectomy”, Circulation, vol. 109, pp. 1476-1481, 2004.
Stathakis, N.E., et al., Platelet Dysfunction in Essential Thrombocythaemia, Annals of Clinical Research, vol. 6, pp. 198-202, 1974.
Thorsen, C. A., et al., “The Treatment of the Hemolytic-Uremic Syndrome with Inhibitors, of Platelet Function”, The American Journal of Medicine, vol. 66, pp. 711-716, Apr. 1979.
Triadou, P., et al., “Platelet Function in Sickle Cell Disease During Steady State”, Nouvelle Revue Francaise Hematologie, vol. 32, pp. 137-142, 1990.
University of Perugia, “Aspirin for the Prevention of Recurrent Venous Thromboembolism and Cardiovascular Events”, pp. 1-3, ClinicalTrials.gov/ct/show/NCT00222677, Sep. 13, 2005.
Yao, S., et al., “Clopidogrel is More Effective Than Aspirin as Adjuvant Treatment to Prevent Reocclusion After Thrombolysis”, Am. J. Physiol., vol. 267, pp. H488-H493, 1994.
Amir, J., et al., “Treatment of Thrombotic Thrombocytopenic Pupura with Antiplatelet Drugs”, Blood, vol. 42, No. 1, pp. 27-33 Jul. 1973.
Antithrombotic Trialists' Collaboration, “Collaborative Meta-Analysis of Randomised Trials of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High Risk Patients”, British Medical Journal, vol. 324, pp. 71-86, 2002.
Balduini, C.L., et al., “Platelet Aggregation in Platelet-Rich Plasma and Whole Blood in 120 Patients with Myeloproliferative Disorders”, Coagulation and Transfusion Medicine, vol. 95, No. 1, pp. 82-86, Jan. 1991.
Bertrand, Michel. E., “Randomized Multicenter Comparison of Conventional Anticoagulation Versus Antiplatelet Therapy in Unplanned and Elective Coronary Stenting: . . . ” Circulation, vol. 98, pp. 1597-1603, 1998.
Brighton, T.A., et al., “Antiphospholipid Antibodies and Thrombosis”, Bailliere's Clinical Haematology, vol. 7, No. 3, pp. 541-557, Sep. 1994.
Caprie Steering Committee, “A Randomized, Blinded, Trial of Clopidogrel Versus Asprin in Patients at Risk of Ischaemic Events (CAPRIE)”, The Lancet, vol. 348, pp. 1329-1339, Nov. 16, 1996.
Collins, C.E. et al., “Review Article:Platelets in Inflammatory Bowel Diease-Pathogenic Role and Therapeutic Implications”, Aliment Pharmacol. Ther., vol. 11, pp. 237-247, 1997.
Davies, M.J., et al., “Intramyocardial Platelet Aggregation in Patients with Unstable Angina Suffering Sudden Ischemic Cardiac Death”, Pathophysiology and Natural History—Platelets, Circulation, vol. 73, No. 3, pp. 418-427, 1986.
Felfernig-Boehm, D., et al., “Early Detection of Preeclampsia by Determination of Platelet Aggregability”, Thrombosis Research, vol. 98, pp. 139-146, 2000.
Caroff Eva
Fretz Heinz
Hilpert Kurt
Houille Olivier
Hubler Francis
Actelion Pharmaceuticals Ltd.
Hoxie & Associates LLC
Rao Deepak
LandOfFree
Pyrimidine derivatives and their use as P2Y12 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine derivatives and their use as P2Y12 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine derivatives and their use as P2Y12 receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4296728